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Background/aim: Based on the antiviral and antibacterial properties of aluminum salts, we aimed to find out the influence of aluminum
salts on COVID-19 infected patients.
Materials and methods: We performed an observational retrospective cohort study which includes the patients diagnosed as COVID-19
and received aluminum salts in addition to actual treatments during hospitalization as the treatment group (Alum Group). Patients
who received standard COVID-19 treatment protocols in the Infectious Diseases Clinics were included as the Control Group. Clinical
findings, laboratory parameters, length of stay, survival, radiological follow-up, intensive care and mechanical ventilation needs, the
presence of comorbidity, polymerase chain reaction (PCR) tests, symptoms, symptom recovery times, hospital stay times, treatment
protocols, and clinical presence of pneumonia were examined in all patients. Advanced chemical composition analyzes of existing
aluminum salts were also performed.
Results: A total of 109 patients, 54 in the alum group and 55 in the control group, were included in the study. None of the patients in the
aluminum group developed side effects due to the intake of aluminum salt. Survival status was significantly different between the two
groups as there were 5 loss in the Control Group and none in the Alum Group (P = 0.023). The symptom recovery time was significantly
shorter in the Alum Group; 2 (1–3) vs. 1 (1–2) days, P = 0.003. According to the paired samples analyses of the comparison between
hospitalization and discharge, CRP levels significantly drops in the Alum Group (from 54.09 to 27, P = 0.001) but not in the Control
Group. The drop was significantly same for the lactate dehydrogenase (LDH) and procalcitonin levels with P = 0.001.
Conclusion: It has been observed that aluminum salts have beneficial effects in COVID-19 infected cases. Considering the low systemic
toxicity of intermittent oral intake of aluminum salts as food supplements and the fact that pandemic control is still not achieved, the
use of aluminum salts is promising.
Key words: Coronavirus (COVID-19), aluminum salts

1. Introduction
Corona viruses are enveloped positive-stranded RNA
viruses and have hazardous effects on both humans and
animals. In February 2020, the World Health Organization
(WHO) designated the disease COVID-19, which stands
for coronavirus disease 2019. Coronaviruses cause severe
respiratory damage and failure. Due to its rapid spread
and complicated infection mechanism, the whole world is
faced with COVID-19 and its severe consequences.
Infection manifests a wide spectrum but the most
frequent clinical presentation is pneumonia. Most of the
patients have fever, cough, dyspnea, and also bilateral
infiltrates on chest imaging and computerized tomography

(CT) [1–4]. Patients with COVID-19 have no specific
laboratory findings but most of them have lymphopenia,
elevated aminotransaminase levels, elevated LDH,
elevated inflammatory markers [e.g., ferritin, C-reactive
protein (CRP), and erythrocyte sedimentation rate], and
abnormalities in coagulation tests [3–5]. In spite of plenty
of attempts and investigations, unfortunately no vaccine
or curative medications have been found. Mortality rate of
COVID-19 is worrisome and varies in different countries.
During the COVID-19 pandemic, the global search
on drugs and vaccines continues; however, a valid and
effective treatment method has not been found yet. The
high infectious capacity of COVID-19 and the increasing
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mortality rates, mostly due to respiratory failure, increase
the seriousness of the situation and the need for medication.
Mortality is higher in cases followed up with mechanical
ventilation after lung involvement of COVID-19.
Aluminum salts, which are common in nature, are also
found in drinking water in trace amounts and have been
used for many years, especially in skin tanning, wound
healing, bleeding control, and many other purposes.
Since aluminum cannot be found pure in nature, it is in
salt forms such as chloride, phosphate, sulphate, nitrate,
ammonium, and acetate. Ammonium aluminum sulphate
and potassium aluminum phosphate salts, which are
known as blood stones in the society, are used to stop
bleeding in a short time in superficial skin bleeding. There
are studies on both antiviral and antibacterial therapeutic
effects of aluminum salts. In addition, aluminum salts
have been used safely for years as an adjuvant in vaccines.
In individuals without renal damage, the toxic effect of
aluminum salts taken intermittently is not observed, and
systemic toxicity findings are not expected since intestinal
absorption is quite low [6–8]. In case of toxicity, the
response to chelation therapies, especially desferoxamine,
is quite good and results in recovery without sequelae
[9,10]. Based on the antiviral and antibacterial properties
of aluminum salts, it has been predicted that oral ingestion
as a food supplement may have a clinically therapeutic
effect against both the prognosis of primary viral disease
and secondary bacterial infections that may develop after/
during? viral infection in COVID-19 infected cases. In this
study we aimed to find out the influence of aluminum salts
on COVID-19 infected patients.
2. Materials and methods
We performed an observational retrospective cohort study
which includes the patients diagnosed with COVID-19
between 10.03.2020 and 10.07.2020 (early pandemic)
and hospitalized at Meram School of Medicine. Patients
who were followed up with the diagnosis of COVID-19
in Internal Medicine Clinics received a daily salt need
(2 g/day aluminum salts) as a food supplement on a
voluntary basis in addition to actual treatments during
hospitalization, and were included in the study as the
treatment group (Alum Group). Patients who received
standard COVID-19 treatment protocols in the Infectious
Diseases Clinics were included as the Control Group.
Aluminum sulphate (Al2(SO4)3) was used as a salt form
in the study. The current study has been approved by the
Necmettin Erbakan University, Meram Faculty of Medicine
Ethics Committee and was performed in accordance with
the rules of the ethics committee.
2. 1. Study design and patients
The patients in the Alum Group took a daily amount of 2
g ground aluminum salts with meals. Only adult patients
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(over 18 years old) were included in the study. Patients in
the Alum Group have completed the COVID-19 standard
treatment protocols completely and regularly until
discharge and afterward. Here, the standard treatment
given to the Alum Group is the same as the current and
global medications applied to the Control Group patients.
The study data were obtained retrospectively through
investigating hospital database and patient files. All
patients’ clinical findings, laboratory parameters, length
of stay, survival, radiological follow-up (chest graphs and
computerized tomography) and responses, presence of
postdischarge sequelae, postdischarge control evaluations,
possible side effect profiles, intensive care, and mechanical
ventilation needs were recorded. In addition to the
COVID-19 laboratory routine examinations, the presence
of comorbidity, PCR tests, symptoms, symptom recovery
times, hospital stay times, treatment protocols, and clinical
presence of pneumonia were examined in all patients.
Besides, advanced chemical composition analyzes of
existing aluminum salts were also performed to compare
the quality and efficacy of aluminum sulphate salts on the
market and to ensure treatment standardization.
2. 2. Chemical analyses of aluminum salts
Since we learned that there are different types of aluminum
salts sold in the market, in order to ensure standardization
in the study, we used an advanced chemical analysis to
make sure that the salt we use is from Kütahya/Turkey (the
purest form). The characteristics of the salt sample used
in the current study are as follows: certain parts of the
selected sample surface are smooth, there are moderately
deep cracks, there are small protrusions on the surface,
and the surface has homogeneous general elemental
distribution (Figure 1). In the sample, as seen in the energy
dispersive spectroscopy (EDS) in Figure 2, although S, K,
and Al elements have a high proportion, it is seen in Figure
3 (the spectrum is given) that there are some impurities
such as Fe in addition to the elements determined as a
result of Energy Dispersive X-ray Fluorescence (ED-XRF)
analysis. A total of 1% change was observed between the
quantitative analysis results of the sample performed
with both devices (Figure 2, Table 1). This change is due
to the use of the oxide structures of the elements in the
calculation of ED-XRF results. Since the EDS analysis gives
results for only the region where the sample is imaged, a
separate analysis has been made with energy dispersive
X-ray fluorescence (ED-XRF) (RIGAKU, Tokyo, Japan)
spectrometer in order to make quantitative analysis of the
whole sample and to determine the oxide structures of
the detected elements. Additionally, quantitative analysis
of elemental distribution with Fe-SEM (Field Emission
Scanning Electron Microscopy) is shown in Figure 3 and
Figure 4.
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Figure 1. Surface imaging under 5kV voltage and 8000× magnification with ZEISS
(Carl Zeiss GmbH, Oberkochen, Germany) Gemini SEM 500 Field Emission Electron
Microscope (Fe-SEM) for salt with Kütahya origin.

Figure 2. Fe-SEM-EDS spectrum and quantitative analysis result.

2. 3. Statistical analyses
Statistical analyses were performed using the IBM Statistics
SPSS Software Version 23 (IBM Corp., Armonk, NY, USA).
The variables were investigated using visual (histograms,
probability plots) and analytical methods (Kolmogorow–
Simirnov/Shapiro–Wilk test) to determine if they are
normally distributed. The chi-square test or Fisher’s exact
test (when chi-square test assumptions do not hold due

to low expected cell counts), where appropriate, was used
to compare these proportions (which proportions?) in
different groups. For the variables that are not normally
distributed, the Mann–Whitney U tests were conducted
for comparison. The Wilcoxon test was used to compare
the nonparametric two-related samples, hospitalization
and discharge. The P-value less than 0.05 was considered
statistically significant for all analyses.
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Table 1. Concentrations of the elements in the sample (ED-XRF
analysis).
SO3

K2O

Al2O3

Fe2O3

mass%

mass%

mass%

mass%

Kütahya

27.8

9.7

7.29

0.0038

Statistical error

0.0281

0.0302

0.0351

0.0004

Detection limit

0.0061

0.0016

0.022

0.0006

Quantization limit

0.0184

0.0048

0.066

0.0019

3. Results
A total of 109 patients, 54 in the Alum Group and 55 in the
Control Group, were included in the study. There were 25
female and 30 male patients in the Control Group, while
there were 26 female and 28 male patients in the Alum
Group. The median age of the Control Group was 58 (44–

Figure 3. Fe-SEM quantitative analysis of elemental distribution.
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70), while it was 58 (44.5–70.25) for the Alum Group. None
of the patients in the aluminum group developed side effects
due to the use of aluminum salt. COVID-19 PCR positivity
was detected in 41 (74.5%) patients in the Control Group
and 13 (24.1%) in the Alum Group (statistically significant P
= 0.001). The rate of comorbidity was similar in both groups:
36 (65.5%) vs. 40 (74.1%) which value belongs to which
group?, P = 0.32. Survival status was significantly different
between the two groups with 5 loss in the Control Group and
none in the Alum Group (P = 0.023). Clinically diagnosed
pneumonia presence rates were similar for both groups:
35 (63.6%) vs. 29 (53.7%) which value belongs to which
group?, P = 0.24. Chest radiography and CT infiltration and
Intensive Care Unit (ICU) follow-up rates were also similar
in two groups (Table 2). While the durations of hospital stay
were similar, the symptom recovery time was significantly
shorter in the Alum Group: median 2 vs. 1 days, P = 0.003.
There was no significant difference for the hospitalization
duration: median 4 vs. 4 days, P = 0.92.
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Figure 4. Results obtained by ED-XRF spectrum.
Table 2. Comparison of clinicodemographic characteristics between Control and
Alum Group patients during hospitalization.
Control (n = 55)

Alum (n = 54)

P valuea

COVID-19 PCR positivity

41 (74.5%)

13 (24.1%)

0.001

Comorbidity

36 (65.5%)

40 (74.1%)

0.32

Survival status

50 (90.9%)

54 (100%)

0.023

Pneumonia presence

35 (63.6%)

29 (53.7%)

0.24

Chest Graph infiltration

33 (60%)

25 (46.3%)

0.26

CT infiltration

32 (58.2%)

30 (55.6%)

0.37

ICU follow-up

7 (12.7%)

3 (5.6%)

0.19

CT: computerized tomography; ICU: Intensive Care Unit.
a
Differences assessed using the χ2- test for categorical variables.

During the hospitalization, white blood cell, neutrophil,
and platelet counts were significantly higher in the Alum
Group (Table 3). While CRP levels were significantly higher
in the Alum Group, the procalcitonin levels were not; 13
vs. 25.5, P = 0.036 and 0.07 vs. 0.1, P = 0.06 respectively.
Fibrinogen levels were significantly higher in the Alum
Group: 340 vs. 396, P = 0.025. At discharge lymphocyte
levels were significantly higher in the Alum Group; 1.49 vs.
1.8, P = 0.018. CRP levels were lower in the Alum Group
but was not significant; 14 vs. 13, P = 0.94 (Table 4).
According to the comparison of the paired samples
analyses during the hospitalization and after discharge,
CRP levels were found to drop significantly in the Alum
Group (from 54.09 to 27, P = 0.001) but not in the Control
Group (Table 5). The drop was significantly same for the
LDH and procalcitonin levels with P = 0.001 (Table 6). The
distributions of symptoms at hospitalization are depicted
in the Figure 5. In order to evaluate the clinical effect of

aluminum salts, the chest radiographs of a patient who used
aluminum salts were taken at 2 days interval (Figure 6).
4. Discussion
Based on the antiviral and antibacterial properties of
aluminum salts, it has been predicted that oral ingestion as
a food supplement may have a clinically therapeutic effect
against both the prognosis of primary viral disease and
bacterial infections that may develop secondary to viral
infection in COVID-19 infected cases. We retrospectively
found that aluminum salts have beneficial effects on both
clinical and laboratory findings in COVID-19 infected
patients. While the effects observed in favor of loss-free
survival and decrease in symptom recovery time, it is also
pleasing that no side effects are observed due to aluminum
salts.
Based on the results of the chemical in terms of the
purity and efficacy of the aluminum salts, we believe that
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Table 3. Comparison of laboratory parameters between Control and Alum Group patients
during hospitalization (median and IQR).
Control (n = 55)

Alum (n = 54)

P valuea

Age

58 (44–70)

58 (44.5–70.25)

0.73

Symptom recovery time

2 (1–3)

1 (1–2)

0.003

Hospitalization stay day

4 (6–9)

4 (5–8)

0.92

SO2

95 (92–97)

95 (92–96)

0.13

Hemoglobin (g/dL)

13.9 (12.8–14.8)

13.10 (11.87–14.52)

0.056

WBC count (x103/µL)

5.75 (4.59–7.18)

7.98 (6–10.42)

0.001

Neutrophil count (x10 /µL)

3.85 (2.98–5.20)

5.89 (3.9–7.53)

0.001

Lymphocyte count (x103/µL)

1.15 (0.87–1.66)

1.22 (0.9–2.05)

0.23

Platelet count (x10 /µL)

191 (145–225)

224 (185–279)

0.002

Creatinine (mg/dL)

0.8 (1–1.24)

0.93 (0.8–1.2)

0.63

AST (IU/dL)

21 16–33)

19 (14–31)

0.31

ALT (IU/dL)

16 (12–25)

16 (11–29)

0.65

CRP

13 (6.7–37)

25.5 (10.3–67.75)

0.036

Sedimentation

26 (14.5–49)

27.5 (15.75–58.5)

0.28

LDH

232 (198–290)

250 (195–313)

0.41

Procalcitonin

0.07 (0.05–0.12)

0.1 (0.05–0.27)

0.07

Ferritin

133 (63–256)

156 (86–649)

0.1

D-DIMER

176 (93–368)

252 (132–650)

0.1

Fibrinogen

340 (292–382)

396 (287–547)

0.025

INR

1 (1–1)

1 (0.94–1.2)

0.15

3

3

SO2: saturation of oxygen.
a
Differences assessed using the Mann–Whitney U test for numerical variables.

treatment standardization is achieved. In addition, this
study should also be taken into account in prospective
studies to be carried out with aluminum salts. Since the
period during which the study was conducted was an
early pandemic, the PCR test could only be performed on
patients who were hospitalized at that time, 48 to 72 h after
hospitalization. The patients in the Alum Group started
taking aluminum salts at the time of hospitalization, and
they used aluminum salts for at least 48 h before the PCR
test was performed. In our study, we believe that the low
PCR-test positivity in the Alum Group developed due to
the possible antiviral activity of aluminum salts within this
delay period. One of the most striking results of this study
is that there is no loss of life in the Alum Group; however,
it would not be right to make an assertive comment
with a retrospective study conducted with a limited
number of patients. In evaluation of the therapeutic
responses of patients to aluminum salts, we found that
there was no inequality? in terms of pneumonia during
hospitalization by clinical and radiological evaluations
carried out in order to evaluate respiratory system
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involvement that most frequently caused mortality in
COVID-19 patients. However, we found that the time
needed for the improvement of the symptoms, which
we considered clinically as a criterion for recovery, was
significantly shorter in the Alum Group. In terms of the
inflammation burden, we found that the white blood
cell (WBC), neutrophil, CRP, and procalcitonin levels
checked during hospitalization were higher in the Alum
Group than in the Control Group, but were lower than in
the Control Group after discharge. In addition, after the
evaluation of parameters with prognostic value such as
the presence of lymphopenia and high fibrinogen in the
follow-up of COVID-19, we found that although the levels
of admission fibrinogen in the Alum Group were higher
than the Control Group, they were lower after discharge,
and similarly, they had higher lymphocyte levels after
discharge.
There is not enough data in the literature regarding
the therapeutic use of aluminum salts in humans. There
are also many toxicity studies. Many adverse events and
complications, especially Alzheimer’s disease, dementia,

DEMİR et al. / Turk J Med Sci
Table 4. Comparison of laboratory parameters between Control and Alum Group patients at
discharge (median and IQR).
Control (n = 55)

Alum (n = 54)

P valuea

96 (95–97)

96 (95–97)

0.51

WBC count (x10 /µL)

5.7 (4.9–7)

7.1 (5.67–8.7)

0.004

Neutrophil count (x103/µL)

3.45 (2.9–4.2)

4.14 (3.44–5.28)

0.014

Lymphocyte count (x10 /µL)

1.49 (0.97–1.98)

1.8 (1.28–2.66)

0.018

Platelet count (x103/µL)

209 (175–274)

241 (196–330)

0.05

Creatinine (mg/dL)

0.94 (0.79–1.1)

0.89 (0.72–1.18)

0.74

AST (IU/dL)

24 (17–40)

18 (13–32)

0.023

ALT (IU/dL)

21 (15–40)

18 (11–36)

0.07

CRP

14 (5–29)

13 (5–39)

0.94

Sedimentation

33 (12–59)

39 (19–56)

0.57

LDH

230 (185–305)

217 (168–279)

0.46

Procalcitonin

0.06 (0.04–0.09)

0.07 (0.04–0.17)

0.63

Ferritin

223 (100–428)

225 (92–625)

0.9

D-DIMER

187 (95–376)

269 (127–569)

0.21

Fibrinogen

366 (271–432)

382 (273–469)

0.64

INR

1 (1–1)

1 (0.9–1)

0.81

SO2
3

3

SO2: saturation of oxygen.
a
Differences assessed using the Mann–Whitney U test for numerical variables.
Table 5. Paired samples comparison of laboratory parameters for Control Group
between hospitalization and discharge (mean ±SD).
Hospitalization

Discharge

P valuea

93.85 ± 4.65

95.69 ± 2.63

0.001

WBC count (×10 /µL)

6.12 ± 2.36

6.71 ± 3.61

0.83

Neutrophil count (×103/µL)

5.57 ± 9.71

4.56 ± 3.61

0.29

Lymphocyte count (×10 /µL)

1.29 ± 0.59

1.54 ± 0.64

0.001

Platelet count (×103/µL)

189.4 ± 56.6

227.7 ± 101.1

0.028

Creatinine (mg/dL)

1.08 ± 0.40

1.08 ± 0.58

0.06

AST (IU/dL)

76.7 ± 358

41.2 ± 51.7

0.51

ALT (IU/dL)

62.8 ± 305

54.2 ± 134.5

0.003

CRP

29.57 ± 37.79

32.26 ± 52.83

0.49

Sedimentation

33.1 ± 27.8

38.4 ± 26

0.58

LDH

260.2 ± 98.8

262.2 ± 123.7

0.72

Procalcitonin

0.1 ± 0.1

3.34 ± 18.88

0.44

Ferritin

218.6 ± 310.1

685.8 ± 1570

0.001

D-DIMER

449.7 ± 829.1

483.2 ± 717.5

0.53

Fibrinogen

355.3 ± 110.8

365.7 ± 106.9

0.96

INR

1.01 ± 0.9

1.05 ± 0.16

0.18

SO2
3

3

SO2, saturation of oxygen.
a
Differences assessed using the Wilcoxon Signed Ranks Test for paired samples.
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Table 6. Paired samples comparison of laboratory parameters for Alum Group between
hospitalization and discharge (mean ±SD).
Hospitalization

Discharge

P valuea

93.45 ± 3.53

95.70 ± 1.84

0.001

8.44 ± 3.50

7.71 ± 3.17

0.02

Neutrophil count (×10 /µL)

6.40 ± 3.41

4.71 ± 2.27

0.001

Lymphocyte count (×10 /µL)

1.49 ± 0.79

2.06 ± 1.14

0.001

Platelet count (×10 /µL)

232.1 ± 80.1

269.5 ± 110

0.055

Creatinine (mg/dL)

1.32 ± 1.27

1.31 ± 1.27

0.06

AST (IU/dL)

40.8 ± 81.4

36.3 ± 87.2

0.59

ALT (IU/dL)

25.1 ±25.8

30.3 ±39.5

0.37

CRP

54.09 ±65.71

27 ±36.45

0.001

Sedimentation

40.2 ±30.6

42.8 ±29.8

0.11

LDH

319.4 ±271.4

302.7 ±472.8

0.001

Procalcitonin

7.16 ±41.2

0.31 ±1.05

0.001

Ferritin

838.3 ±3216

371.4 ±346.8

0.86

D-DIMER

630.3 ±847.1

608.2 ±1213

0.21

Fibrinogen

431.4 ±175.7

382.1 ±125.8

0.11

INR

1.12 ±0.36

1.11 ±0.43

0.36

SO2
WBC count (×10 /µL)
3

3

3

3

SO2: saturation of oxygen.
a
Differences assessed using the Wilcoxon signed ranks test for paired samples.

Figure 5. Distribution of symptoms at hospitalization for Control (A) and Alum (B) Groups.

and kidney failure are mentioned due to chronic and
high dose intake of aluminum salts. However, the
beneficial effects of aluminum salts such as antiviral and
antibacterial effects are also known. Foot-and-mouth
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disease (FMD) or hoof-and-mouth disease (HMD)
is an infectious and sometimes fatal viral disease that
affects cloven-hoofed animals, including domestic and
wild bovid [11,12]. Aphthovirus is a viral genus of the

DEMİR et al. / Turk J Med Sci

Figure 6. The chest radiographs of a patient who used aluminum salts, taken at 2 days interval.

family Picornaviridae. Aphthovirus infect split-hooved
animals, and include the causative agent of foot-andmouth disease. Foot-and-mouth disease virus (FMDV)
is the prototypic member of the genus Aphthovirus [13].
In our country, animals suffering from foot and mouth
disease are treated quite successfully with the topical use of
aluminum salts. As it is known, aluminum salts have been
used safely for years as an adjuvant in vaccines. In a study
conducted with aluminum chloride salts, it was observed
that the adsorption of the virus to the filter increased [14].
Skin wraps impregnated with aluminum acetate have been
found to have an effective antibacterial activity [15]. In a
study performed with rabbit alveolar macrophages, it has
been shown that in vitro aluminum chloride hydroxide salt
increases the phagocytic effect [16]. In a recently published
study, it was stated that aluminum ammonium salts have a
very effective topical disinfectant effect, especially against
nosocomial infectious agents, which occurs within seconds
[17].
In our study, no side effects and toxicity were observed
due to the intake of daily 2 g of aluminum salts of the patients
with meals. In addition, since the patients took aluminum
salts with meals, there were no tolerance and adaptation
problems. Aluminum salts are very easy to procure and are
very cheap. As we found in our study, the recovery time
for the symptoms is quite short. Although the patients in
the Alum Group received aluminum salts in addition to
the current COVID-19 treatments and treatments were
applied in different protocols, no drug interaction and
complications were detected in any patient. In our study, we
think that better results can be obtained with higher doses
because patients took aluminum salts at the lowest dose (as
much as the daily salt need) for safety precautions.

Due to the retrospective nature of the study, a
limited number of cases were examined with inadequate
methodology. Due to the limitation in PCR test in the
early pandemic period, most patients could only be tested
after the treatment was started, which is a factor that
reduces the reliability of the test. Another negative factor is
that patient data are not recorded at the desired standard.
However, despite all these negativities, the current study is
the first and only study done in this concept so far.
As a result, it has been observed that aluminum salts
have beneficial effects both clinically and in the laboratory
on COVID-19 infected cases. Considering the low
systemic toxicity of intermittent oral intake of aluminum
salts as food supplements and the fact that pandemic
control is still not achieved, the use of aluminum salts is
promising. In the future, through the prospective studies
with more patients, we can make clearer comments on
the contribution of aluminum salts to both treatment and
prophylaxis of COVID-19 infected patients.
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